Aspireo reports positive preliminary data from Somatoprim phase Ib study

The study conducted in a single center was designed to assess the safety, side effect profile in addition to pharmacokinetic and pharmacodynamic profile of varying doses of Somatoprim.

Healthy male volunteers were administered with either Somatoprim alone or in combination with octreotide in the study.

The preliminary data indicates good safety and side effect profile of Somatoprim while no serious adverse events were observed.

Upon the stimulation by growth hormone releasing hormone, Somatoprim demonstrated a dose-dependent lowering effect on growth hormone (hGH) comparable to an analysis of the pharmacodynamic effect on hGH.

Aspireo anticipates reporting final data in the second quarter of 2013.